Premium
Immunohistochemical analysis of Ki‐67 antigen and Bcl‐2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy
Author(s) -
Tsuji,
; Murakami,
Kanayama,
Sano,
Kagawa
Publication year - 1998
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1046/j.1464-410x.1998.00492.x
Subject(s) - immunohistochemistry , hormonal therapy , medicine , prostate cancer , prostatectomy , stage (stratigraphy) , antigen , prostate specific antigen , cancer , prostate , androgen , oncology , adjuvant , proliferative index , hormone , biology , immunology , paleontology
Objective To determine differences in the immunohistochemical (IHC) expression of Bcl‐2 protein and Ki‐67 antigen in patients with prostatic cancer who underwent radical prostatectomy with or without neo‐adjuvant hormonal therapy. Materials and methods Ki‐67 antigen and Bcl‐2 protein were detected by IHC using MIB‐1 and Bcl‐2 antibodies in prostatectomy specimens from 28 patients who received hormonal therapy before surgery (group 1) and 51 patients who did not (group 2). Results In group 2, the mean MIB‐1 index increased with increasing grade of tumour, from 11.6% in low‐grade to 24.7% in high‐grade tumours ( P =0.002). Bcl‐2 expression did not correlate with either tumour grade or stage. In group 1, there were no correlations between Bcl‐2 expression or MIB‐1 index and tumour grade or stage. More tumours in group 1 were Bcl‐2‐positive (16 of 28, 57%) than were tumours in group 2 (11 of 51, 22%; P =0.003). The mean (sd) MIB‐1 index of tumours in group 2 [15.6 (14.4)%], was significantly greater than that of tumours in group 2 [6.8 (7.5)%; P =0.004]. Conclusions These results indicate that Bcl‐2 positivity is increased by androgen ablation therapy and conversely, that the proliferative activity of cancer cells is significantly reduced. The expression of Bcl‐2 protein may play a role in the ability of prostate cancer cells to survive in an androgen‐deprived environment.